Autologous Cell Therapy Market
Autologous Cell Therapy Market (Source - Bone Marrow and Epidermis; Application - Neurology, Orthopedics, Cancer, Wound Healing, CVD, and Autoimmune; End User - Hospitals, Ambulatory Centers, and Research Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
- Category : Healthcare
- Format :
Press Release :
Global Autologous Cell Therapy Market: Overview
Autologous cell therapy refers to infusion or transfer of human tissue or cells back to the same person for treating a diseased part. For the same purpose, stem cells are removed from the patient, harvested, cultured, and once again transplanted to the same person. The purpose of this method is to reduce the chances of rejection to the treatment by the body. Furthermore, autologous cell therapy does not even require immunosuppression. The growing number of cancer patients have triggered a significant demand for autologous cell therapy. According to the research report, the global market projected to reach a valuation of US$23.7 bn by the end of 2024 as compared to US$3.8 bn in 2015. During the forecast period of 2016 and 2024, the global market is estimated to exhibit a CAGR of 21.9%.
Unmet Medical Needs and Cost-effectiveness of Autologous Cell Therapy Drives Demand
The global market is expected to grow due to the huge pool of unmet medical needs for cell based therapy, growing government support for cell-based research, and rising number of technological innovations in cell based therapies. Currently, cell therapy is considered a promising technique for several conditions such as neurological, orthopedic, oncology, and a wide range of autoimmune diseases. The ability of stem cells to transform into a cartilage, tendon, bone (osteoblast), and muscle has given this market a fresh lease of life. The biggest advantages of autologous cells is the fact that it is relatively cost-effective, allows quick access to blood as it is derived from the patient, ensures easy method of production, and comes with the lowest threat of disease transfusion. All of these factors have been consistently boosting the demand for autologous cell therapy in recent years.
Supportive Government Policies across North America Favor Regional Market
Geographically, the market has been divided into Asia Pacific, North America, Europe, the Middle East and Africa, and Latin America. North America holds a dominant position in the global market and is expected to maintain its stance in the coming years as well. The strengthening health care infrastructure and supportive government policies are expected ensure high adoption of autologous cell therapy in North America in the near future. The analysts estimate that Asia Pacific will also register a robust CAGR in the coming years. The growth of this market in Asia pacific will be driven by the proliferating medical tourism industry, increasing contract research activities, and economic growth of certain developing countries such as India and China.
Hospitals to Retain Dominance in Global Market over Forecast Period
The end users of autologous cell therapy are hospitals, research centers, and ambulatory centers. Of these, the hospitals dominated the global market in 2015 and are expected to continue its dominance till the end of 2024 as the surgical procedures continue to be on the rise across hospitals. The research report indicates that the ambulatory surgical centers segment will also expand at a significant rate in the coming years as it is known to reduce waiting time period before surgery, growing outpatient surgical procedures, high confidentiality and privacy of the data, and cost-effective procedure.
Some of the leading players operating in the global market are Major players operating in this Market are Vericel Corporation, BioTime, Inc., Pharmicell Co., BrainStorm Cell Therapeutics, Opexa Therapeutics, Inc, Pharmicell Co., Inc.
Global Autologous Cell Therapy Market: Overview
This report provides in-depth region wise and country wise analysis of the autologous cell therapy market. Stakeholders of this report include manufacturers of cell therapy products, raw material suppliers, cancer drug processing companies, and new players planning to enter the market.
The report provides qualitative and quantitative analysis of this market. Qualitative analysis comprises market dynamics, trends, product overview, and country-level market information. Quantitative analysis includes major players with their reported revenue, market size, and forecast for the global market in major countries globally such as the U.S., Canada, Germany, France, United Kingdom, Switzerland, Spain, Japan, China, Brazil, Mexico, South Africa and Saudi Arabia. Market revenue is provided in terms of US$ Mn from 2014 to 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 for all the segments, considering 2015 as the base year. The executive summary of the report provides a snapshot of the autologous cell therapy with information on leading segments, country wise market information with respect to the market size, growth rate (CAGR %), and growth factors. Moreover, the report also includes pipeline analysis (phase I & II) of the autologous cell therapy market on basis of disease conditions.
Global Autologous Cell Therapy Market: Drivers and Trends
The market overview section comprises impact factors such as drivers, restraints, and opportunities for this market. These factors would aid the stakeholders in establishing a strong foothold in the global market. Furthermore, the market overview section comprises key industry events, product overview, market attractiveness analysis and emerging trend in the market. The market attractiveness analysis provides a graphical view comparing the growth and market dynamics in various segments and country wise to identify the most attractive market.
Global Autologous Cell Therapy Market: Segmentation
The autologous cell therapy market has been segmented as source, application, end-user and geography. Based on source, the market has been segmented into bone marrow, epidermis and others. Likewise, on basis of application the market has been categorized into neurology, orthopedic, cancer, wound healing, CVD, autoimmune, and others. Hospitals, ambulatory centers and research centers are included into the market by end-user.
Global Autologous Cell Therapy Market: Regional Outlook
Geographically, this market has been categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Moreover, analysis for the major countries comprising U.S. Canada, Germany, U.K., France, Switzerland, Spain, Japan, China, Brazil, Mexico, South Africa and Saudi Arabia have also been provided in the report. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the market in various regions has been provided in this section.
This report also includes various ups and downs about particular country or geography that has impacted the overall market globally. The report provides a detailed outline/blueprint of this market globally that will assist new companies in establishing their presence and market players in expanding their market share in the market.
Key Players Mentioned in the Report are:
The report concludes with the company profile section which includes company overview, financial overview, SWOT analysis, product portfolio, business strategies and recent developments for market players. The major players that are profiled in the report include BIOTIME, INC., BrainStorm Cell Therapeutics, Caladrius Biosciences, Inc., Vericel Corporation, Pharmicell Co., Inc., TiGenix N.V., Fibrocell Science, Inc. and Opexa Therapeutics, Inc. among others.
The global autologous cell therapy market has been segmented into:
|
by Source |
|
|
by Application |
|
|
by End User |
|
|
by Geography |
|
